- Home
- HQI vs RAPT Comparison
HQI vs RAPT Comparison
Compare HQI & RAPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HQI
- RAPT
- Stock Information
- Founded
- HQI 2002
- RAPT 2015
- Country
- HQI United States
- RAPT United States
- Employees
- HQI N/A
- RAPT N/A
- Industry
- HQI Professional Services
- RAPT Biotechnology: Pharmaceutical Preparations
- Sector
- HQI Consumer Discretionary
- RAPT Health Care
- Exchange
- HQI Nasdaq
- RAPT Nasdaq
- Market Cap
- HQI 143.3M
- RAPT 122.9M
- IPO Year
- HQI N/A
- RAPT 2019
- Fundamental
- Price
- HQI $9.97
- RAPT $8.04
- Analyst Decision
- HQI Strong Buy
- RAPT Buy
- Analyst Count
- HQI 2
- RAPT 5
- Target Price
- HQI $16.00
- RAPT $42.00
- AVG Volume (30 Days)
- HQI 12.4K
- RAPT 109.8K
- Earning Date
- HQI 08-07-2025
- RAPT 08-07-2025
- Dividend Yield
- HQI 2.35%
- RAPT N/A
- EPS Growth
- HQI N/A
- RAPT N/A
- EPS
- HQI 0.24
- RAPT N/A
- Revenue
- HQI $33,651,000.00
- RAPT N/A
- Revenue This Year
- HQI N/A
- RAPT N/A
- Revenue Next Year
- HQI $4.99
- RAPT N/A
- P/E Ratio
- HQI $39.19
- RAPT N/A
- Revenue Growth
- HQI N/A
- RAPT N/A
- 52 Week Low
- HQI $9.04
- RAPT $5.67
- 52 Week High
- HQI $15.75
- RAPT $30.60
- Technical
- Relative Strength Index (RSI)
- HQI 49.96
- RAPT 62.95
- Support Level
- HQI $9.78
- RAPT $7.04
- Resistance Level
- HQI $10.24
- RAPT $8.91
- Average True Range (ATR)
- HQI 0.23
- RAPT 0.84
- MACD
- HQI 0.02
- RAPT 0.08
- Stochastic Oscillator
- HQI 57.41
- RAPT 92.53
About HQI HireQuest Inc. (DE)
HireQuest Inc is a nationwide franchisor of offices providing direct-dispatch, executive search, and commercial staffing solutions in the light industrial and blue-collar segments of the staffing industry and traditional commercial staffing. The company's franchisees provide various types of temporary personnel through two business models operating under the trade names HireQuest Direct, HireQuest, Snelling, DriverQuest, HireQuest Health, Northbound Executive Search, and MRI. The company's primary source of revenue is royalty fees based on the operation of its franchised offices.
About RAPT RAPT Therapeutics Inc.
RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small-molecule therapies for patients with some unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues.